Hot Stocks: Brokerages on Orchid Pharma, D-Mart, NOCIL and Chola Investment

December 8, 2023

Investec maintained a buy rating on Orchid Pharma with a target price of Rs 800. The company is set for strong growth over the next 3 years. The new management continues to execute the turnaround strategy well. It sees a strong 35%+ EBITDA CAGR over FY23-26 for the base biz (ex-PLI).

More To Explore

Retail inflation at 6.2 per cent dims early rate cut hopes

India’s retail inflation unexpectedly jumped to a 14-month high of 6.2% in October, driven by soaring vegetable, fruit, and edible oil prices. This surge breaches

November 13, 2024

Market tanks again as FPIs keep selling

Technical analysts do not see a rebound in the markets in the near-term. “Nifty is currently around its crucial support of 23,800 and we see

November 13, 2024

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003